Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
IDH1 R132H Decitabine oligodendroglioma sensitive detail...
FGFR3 - TACC3 PRN1371 oligodendroglioma sensitive detail...
IDH1 mutant N/A oligodendroglioma not applicable detail...
IDH2 mutant N/A oligodendroglioma not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT00303849 Phase Ib/II Filgrastim Etoposide + Melphalan Carboplatin Pegfilgrastim Combination Chemotherapy With BBBD Followed By Sodium Thiosulfate in Treating Patients With Anaplastic Oligodendroglioma or Oligoastrocytoma Recruiting
NCT01052363 Phase I Bevacizumab + Fosbretabulin OXC401-PO1s/WVU 1309 - A Pilot Study of Fosbretabulin With Bevacizumab in Recurrent High-Grade Gliomas Withdrawn
NCT01140568 Phase II Nilotinib Study of Platelet Derived Growth Factor Receptor (PDGFR) in Recurrent Malignant Gliomas Completed
NCT01188096 Phase II Poly ICLC A Trial of Poly-ICLC in the Management of Recurrent Pediatric Low Grade Gliomas Unknown status
NCT01339039 Phase I Bevacizumab + Plerixafor Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma Terminated
NCT01392209 Phase I Bevacizumab Hypofractionated Stereotactic Radiotherapy With Bevacizumab in the Treatment of Recurrent Malignant Glioma Completed
NCT01434602 Phase Ib/II Everolimus + Sorafenib Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas Recruiting
NCT01721577 Phase Ib/II AXL1717 Phase I/II Trial of Safety and Anti-tumor Efficacy of AXL1717(Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas Unknown status
NCT01884740 Phase Ib/II Bevacizumab + Cetuximab Phase I/II Trial Of Super-Selective Intraarterial Infusion Of Erbitux and Bevacizumab For Treatment Of Relapsed/Refractory Intracranial Glioma In Patients Under 22 Years Of Age Recruiting
NCT01891747 Phase Ib/II Bevacizumab + Temozolomide A Phase I/II Study of High-dose L-methylfolate in Combination With Temozolomide and Bevacizumab in Recurrent High Grade Glioma Active, not recruiting
NCT01977677 Phase Ib/II Temozolomide Plerixafor Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma Completed
NCT01999270 Phase I Bevacizumab + Irinotecan Evaluation of FDOPA-PET/MRI in Pediatric Patients With CNS Tumors Completed
NCT02052778 Phase Ib/II Futibatinib A Study of TAS-120 in Patients With Advanced Solid Tumors Active, not recruiting
NCT02078648 Phase Ib/II SL-701 Poly ICLC Bevacizumab Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme Completed
NCT02101905 Phase I Lapatinib Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma Active, not recruiting
NCT02238496 Phase II Perifosine + Temsirolimus Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas Active, not recruiting
NCT02423525 Phase I Afatinib Safety Study of Afatinib for Brain Cancer Recruiting
NCT02549833 Phase I GBM6-AD lysate protein vaccine + Poly ICLC Neo-adjuvant Evaluation of Glioma Lysate Vaccines in WHO Grade II Glioma Recruiting
NCT02924038 Phase I IMA950 + Poly ICLC Varlilumab A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG) Recruiting
NCT03220646 Phase II Abemaciclib The Purpose of This Study is to Test Any Good and Bad Effects of a Study Drug Called Abemaciclib (LY2835219) in Patients With Recurrent Brain Tumors. Recruiting
NCT03295396 Phase II ONC201 ONC201 in Adults With Recurrent High-grade Glioma Recruiting
NCT03343197 Phase I Ivosidenib AG-881 Study of AG-120 and AG-881 in Subjects With Low Grade Glioma Active, not recruiting
NCT03514069 Phase I Ruxolitinib Ruxolitinib + Temozolomide Ruxolitinib With Radiation and Temozolomide for Grade III Gliomas and Glioblastoma Recruiting
NCT03969706 Phase II Abemaciclib Abemaciclib in Patients With Oligodendroglioma Active, not recruiting
NCT03975829 FDA approved Dabrafenib + Trametinib Pediatric Long-Term Follow-up and Rollover Study Recruiting
NCT03991832 Phase II Durvalumab + Olaparib Study of Olaparib and Durvalumab in IDH-Mutated Solid Tumors Not yet recruiting
NCT04164901 Phase III AG-881 Study of AG-881 in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO) Recruiting
NCT04295759 Phase I INCB7839 INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas Recruiting